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We show that the allele-dependent expression of transcripts encoding soluble HLA-DQb chains is deter-
mined by branchpoint sequence (BPS) haplotypes in DQB1 intron 3. BPS RNAs associated with low inclusion
of the transmembrane exon in mature transcripts showed impaired binding to splicing factor 1 (SF1), indicat-
ing that alternative splicing of DQB1 is controlled by differential BPS recognition early during spliceosome
assembly. We also demonstrate that naturally occurring human BPS point mutations that alter splicing
and lead to recognizable phenotypes cluster in BP and in position 22 relative to BP, implicating impaired
SF1–BPS interactions in disease-associated BPS substitutions. Coding DNA variants produced smaller fluc-
tuations of exon inclusion levels than random exonic substitutions, consistent with a selection against
coding mutations that alter their own exonization. Finally, proximal splicing in this multi-allelic reporter
system was promoted by at least seven SR proteins and repressed by hnRNPs F, H and I, supporting an
extensive antagonism of factors balancing the splice site selection. These results provide the molecular
basis for the haplotype-specific expression of soluble DQb, improve prediction of intronic point mutations
and indicate how extraordinary, selection-driven DNA variability in HLA affects pre-mRNA splicing.
INTRODUCTION
Alternative pre-mRNA splicing (AS), or a generation of mul-
tiple transcripts from a single pre-mRNA, is a fundamental
mechanism of regulating gene expression and generating pro-
teomic diversity (1). The estimated frequency of human genes
that undergo AS has risen dramatically from 5% to well over
50% in the last decade (2), but the proportion of the AS events
that have functional consequences is currently unknown (3).
The recognition of splice sites involves cross-talk between
multiple interactions that contribute to complexes that commit
the pre-mRNA to splicing. The splicing reaction occurs in the
spliceosome, which consists of the pre-mRNA substrate, four
small nuclear ribonucleoprotein particles (snRNPs U1, U2,
U4/U6 and U5) and a large number of proteins (4). In higher
eukaryotes, the requirement for accurate splicing is accom-
panied by weakly conserved consensus sequences: the 50 splice
sites, 30 splice site, polypyrimidine tract (PPT) and branch point
sequence (BPS). These elements are necessary but often insuffi-
cient to define exon–intron boundaries. Auxiliary cis-elements
that activate or repress splicing, known as exonic and intronic
splicing enhancers or silencers (ESEs, ISEs and ESSs, ISSs),
allow the genuine splice sites to be correctly recognized among
pseudo-splice sites with similar signal sequences. These
cis-elements have been identified through mutations that alter
splicing, through computational comparisons and through the
selection of sequences that activate splicing or bind to splicing
regulatory proteins, most notably a family of serine–arginine
(SR) proteins (5–9). Disease-causing mutations that affect spli-
cing have contributed to our understanding of splicing signal
sequences; however, the influence upon splicing of naturally
occurring DNA polymorphisms has not been systematically
studied.
Genes encoding histocompatibility leukocyte antigens
(HLA) are among the most polymorphic loci in the human
genome. A high, selection-driven DNA variability of both
class I and class II genes is instrumental for the development
of adaptive immune responses; the absent or diminished
expression of the latter, results in immunodeficiency
(reviewed in 10). Although the HLA genes are the most
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important genetic risk factors for the development of a large
number of autoimmune disorders, including multiple sclerosis,
rheumatoid arthritis, juvenile diabetes and narcolepsy, it is not
known how their AS is controlled.
Alternatively spliced HLA isoforms that lack exons enco-
ding the transmembrane domains enter the endocytic com-
partment, are released by cells and can be detected as soluble
molecules (sHLA) in body fluids (11,12). sHLAs have been
shown to induce apoptosis of alloreactive cells in vitro and
modulate immune responses (13,14). Their serum levels are
increased in inflammatory and autoimmune diseases and cor-
relate positively with disease activity and autoantibody titres
(12). In addition, sHLA levels in normal individuals have
been linked to HLA haplotypes, with the highest sHLA class II
concentration in individuals carrying DR3 and DR4 alleles
(15), but mechanisms underlying their haplotype-dependent
expression have not been elucidated.
HLA-DQB1 shows variable inclusion of two exons in
mature transcripts. Exon 5, which encodes the cytoplasmic
portion of DQb, is incorporated into mRNA only on alleles
that have a IVS4–1A!G substitution at the splice acceptor
site. Although both alternatively spliced isoforms restrict anti-
gens, transfectants lacking exon 5 were somewhat less effi-
cient at comparable expression levels than those containing
this exon (16). Exon 4, which codes for the transmembrane
domain of DQb, is differentially included in mRNA in cell
lines carrying particular homozygous DQB1 genotypes (11),
but the molecular mechanism for the allele-dependent pro-
duction of sDQb chains is not understood.
Here we show that BPS and PPT variants in intron 3 are
major determinants of the allele-specific production of DQB1
transcripts lacking exon 4 (D4). Relative levels of DQB1 iso-
forms were markedly influenced by two single nucleotide poly-
morphisms (SNPs) in BPS, implicating naturally occurring BPS
haplotypes in AS. Exon inclusion levels of BPS haplotypes cor-
related with in vitro binding of splicing factor 1 (SF1) to BPS
RNAs. In addition, we also demonstrate a biased distribution
of disease-causing point mutations in human BPS (hBPS) and
propose that impaired SF1–BPS interactions early during spli-
ceosome contribute to splicing defects in these cases. Moreover,
we show that AS of this multi-allelic reporter is controlled by at
least seven SR proteins and at least three heterogenous nuclear
ribonucleoproteins (hnRNPs) and provide a mechanistic expla-
nation for their opposite effects on splice site selection. Finally,
we show how subphysiological temperatures alter the allele-
specific expression of DQB1 isoforms and propose that the
observed changes in exon inclusion may account for tempera-
ture-sensitive course of autoimmune disorders associated with
high D4.
RESULTS
Identification of cis-acting elements that control
differential exon 4 inclusion
To determine factors responsible for the allele-specific pro-
duction of D4, we first characterized DQB1 exon 4 splicing
in a panel of lymphoblastoid cell lines homozygous at
DQB1. We confirmed the absence of D4 in cell lines carrying
DQB102 and 05 alleles (Fig. 1A) that do not secrete
sDQb (11). We next constructed minigenes derived from
D4-producing and non-producing lineages (Fig. 1B) and
determined exon inclusion levels after transient transfection
of the wild-type constructs into HeLa and 293T cells
(Fig. 1C). The allele-specific minigenes retained the signals
required for differential exon inclusion in both cell types, indi-
cating that D4 variability is determined by polymorphisms
within the constructs. To define these cis-elements, we
sequenced flanking introns in homozygous cell lines carrying
10 DQB1 alleles that are common in the population. We found
Figure 1. Alternative splicing of DQB1 exon 4 is determined by cis-regulatory
elements. (A) Differential exon 4 skipping levels in homozygous cell lines.
RT–PCR was with upper (T31–32, T37, T41) and lower (T28–29, T40) hap-
lotype-specific primers. Exon inclusion (EI) levels were measured from dupli-
cate cultures. DQB1 exons 3, 4 and 6 are shown as white, grey and black
boxes, respectively. (B) Allele-specific minigenes. Exons (boxes, E) and
introns (lines) are to scale; scale units are kilobases (kb). All primers
(arrows) are shown in Supplementary Material, Table S1. An open rectangle
at the 30 splice site of intron 3 indicates a multiple sequence alignment
shown in Fig. 2A. (C) Transient D4 levels following transfection of wild-
type minigenes into HEK293T and HeLa cells. Amplification was with
vector primers PL3 and PL4. Mean and SD were derived from three duplicate
transfections. (D) The nucleotide diversity (P(i ), 93) in DQB1 intron 3.
Nucleotide sequences of introns 3–5 are available from Genbank (Accession
nos AY553273–AY553292).
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a total of 65 polymorphisms in intron 3 and 112 polymorph-
isms in intron 4/5, excluding the sites with alignment gaps.
The nucleotide variability was notably higher in the 30 part
of the intron than in the 50 part (Fig. 1D), suggesting intron
homogenization in the region adjacent to b2-encoding exon 3.
To identify SNPs that determine differential splicing, a
minigene producing a mixture of exon inclusion and skipping
(0602 ) was individually mutated in eight exonic and 10
flanking intronic SNPs revealed by multiple sequence align-
ments (Fig. 2A and B). IVS3-24A!T and IVS3-6C!T
mutations strikingly reduced D4, whereas the remaining intro-
nic SNPs, including those close to the 30 (Fig. 2B) and 50
(IVS4þ14A/G, IVS4þ33G/C, data not shown) splice sites,
resulted in minor or no D4 alterations. Mutations in most
exonic SNPs altered D4 levels, but to a smaller extent than
IVS3-24 or IVS3-6 (Fig. 2C). To confirm the importance of
SNPs that influence D4, we introduced mutations in the
same positions into a minigene that contained IVS3-24T/-6T
and produced virtually no D4 (050101). Measurement of
low D4 levels with a sensitive real-time RT–PCR assay
(Supplementary Material, Fig. S1) showed that maximum
exon skipping was conferred by IVS3-24T!A followed by
IVS3-6T!C (Fig. 2D). In addition, IVS-26A!G substantially
reduced exon 4 inclusion of both 0602 and 050101minigenes
(Fig. 2B and D), indicating that IVS3-26, -24 and -6 were key
SNPs responsible for differential splicing of both DQB1 alleles.
Exon 4 inclusion is determined by BPS haplotypes
The SNPs IVS3-24 and -26 were within the best match to the
hBPS consensus (YNYURAY) near the 30 splice site (Fig. 2A).
A pre-mRNA substrate consisting of DQB1 exons 3 and 4 and
complete intron 3 was spliced in vitro (Fig. 3A) and the BP
was mapped by reverse transcription across the 50 –20 bond
of the BP, followed by inverse PCR (17) and sequencing
(Fig. 3B). The identification of A-22 as the BP was further
supported by complete exon skipping caused by mutation
222A!G and deletion IVS3D-21–27, whereas the replace-
ment of the same heptamer with the yeast consensus
UACUAAC (yBPS), which is the preferred mammalian BPS
(18), dramatically improved exon inclusion (Fig. 2B).
Together, these results indicated that IVS3-21–27, which con-
tains two SNPs, is the BPS of exon 4.
Next, we systematically examined how each of the six BPS
haplotypes controls exon inclusion (Fig. 3C). Adenine to
uracil substitutions at position 22 relative to BP (BP-2;
IVS-24) had the strongest effect. The A226T224 haplotype
gave the lowest D4 levels, with a repressive hierarchy A226
T224 . G226T224 . A226C224 . A226A224 . G226C224.
G226A224 on D4. Accordingly, homozygous cell lines
Figure 2. IVS3-24/IVS3-26 in BPS and IVS3-6 in PPT are key SNPs for
differential exon 4 inclusion. (A) Multiple alignments of DQB1 pre-mRNAs
at the 30 splice site of intron 3. Intronic sequence is in lower case, exonic
sequence is in upper case. Stars denote SNPs, dash indicates a single nucleo-
tide deletion. BPS is shaded and BP adenosine is shown as a˚. The designation
of DQB1 alleles is according to the World Health Organization Nomenclature
Committee (102). The following alleles (cell lines) were sequenced:
DQB10201 [cell line VAVY, the 10th International HLA Workshop
number (IHW) 9023], DQB10202 (MOU MANN, IHW9050),
DQB1030101 (LUY, IHW9070; TUBO, IHW9045; AMALA, IHW9064),
DQB1030201 (BOLETH, IHW9031; YAR, IHW9026; PE117, IHW9028;
WT51, IHW9029; BM14, IHW9033; SAVC, IHW9034; MT14B,
IHW9098), DQB1030302 (T7526, IHW9076), DQB10401 (LKT3,
IHW9107), DQB10402 (MADURA, IHW9069), DQB1050101 (KAS116,
IHW9003), DQB1050201 (AZH, IHW9293); DQB1050301 (WT52,
IHW9306; TEM, IHW9057; KOSE, IHW9056), DQB10601 (E4181324,
IHW9011), DQB10602 (SCHU; IHW9013), DQB10603 (OMW;
IHW9058), DQB10604 (WT47, IHW9063; KOSE, IHW9056), DQB10609
(HO301, IHW9055). All the cell lines were homozygous at DQB1, except
for KOSE. a,b,cThe sequences were identical to the GenBank entries
U92032, Z80898 and AL662789, respectively. Alignments of exon 4
sequences are available from the IMGT/HLA database (102). (B) Exon
inclusion levels of minigenes carrying a D4-producing allele (0602) and
mutated in intron 3 SNPs and in BPS. yBPS is the yeast BPS consensus
sequence. (C) Exon inclusion levels following mutations in exon 4 SNPs.
(D) Exon inclusion of minigenes carrying a non-skipping allele and mutated
in the intronic SNPs.
Human Molecular Genetics, 2004, Vol. 13, No. 24 3191
carrying the A226T224 haplotype produced less D4 than cells
with other BPS haplotypes (Fig. 1A and C). However, BPS
variation alone could not explain high D4 observed in
G226T224-carrying cell lines, implicating IVS3-13 and
other intronic SNPs in differential exon skipping, as exon 4
is identical on the DQB103/04 alleles.
BPS haplotypes associated with the lowest exon inclusion
are absent in the population
Initial sequencing of DQB1 alleles in homozygous cells
did not identify the G226A224 and G226C224 haplotypes
that yielded the highest D4 (Fig. 3C). We therefore sequenced
BPS of additional DQB1 alleles associated with IVS3-26G
or -24A/C. Without exception, homozygous cell lines
carrying IVS3-26G and -24A/-24C had -24T and -26A,
respectively (Fig. 2A). In addition, genotyping of over 1600
Caucasian chromosomes using a haplotype-specific (Fig. 3D)
amplification refractory mutation system (ARMS)–PCR (19)
did not reveal these haplotypes. These observations prompt
the hypothesis that these intronic sequences may have been
subject to negative selection through diminished expression
of natural transcripts, leading to immunodeficiency and
predisposition to infections.
Impaired interactions of SF1 with BPS RNAs that
produce high D4
During spliceosome assembly the BPS is recognized first by
splicing factor 1 (SF1; branchpoint binding protein) in the
early (E) complex (20,21), and later by base-pairing with
U2 snRNA in the A complex (22–24). The influence of
BPS haplotypes on exon 4 splicing could be mediated by
the interactions of either or both of these trans-acting factors
with the BPS.
To test if SF1 binding to BPS haplotypes correlates with
exon inclusion, we examined the interaction between small
synthetic BPS-containing RNAs with wild-type and mutated
Figure 3. Alternative splicing of DQB1 exon 4 is controlled by BPS haplo-
types. (A) In vitro splicing of DQB1050101 pre-mRNA in the presence
(þ) and absence (2) of nuclear extracts. The remaining products of the spli-
cing reaction are not shown. (B) DQB1 IVS3 branchpoint adenosine maps to
position 222. The black line indicates the 50 end of IVS3 BPS and the grey
line indicates the 50 end of the intron. BP at A-22 itself was not used as a tem-
plate during the RT reaction. (C) Exon inclusion levels of the DQB1 con-
structs mutated in BPS. Mean and SD were derived from three duplicate
transfections. The population prevalence of BPS haplotypes was estimated
from published frequencies of DQB1 alleles in white Americans (103), assum-
ing absolute linkage disequilibrium between IVS3-24 and exon 2 specificities.
(D) Specificity of ARMS–PCR to detect BPS GA-haplotypes. Arrow indicates
a GA-containing product amplified using allele-specific PCR with plasmid
templates carrying the indicated BPS haplotypes.
Figure 4. Impaired SF1 interactions with BPS RNAs. (A) Wild-type SF1.
Recombinant SF1 (0.68, 1.36, 2.72 and 5.44 mg) was incubated with short
RNAs representing BPS haplotypes as described (21). (B) Mutated SF1.
Mutations were introduced in residues that interact with BP-2 (L244, L247,
R160) and BP-4 (R255 and possibly L254; 21). (C) Expression of mutated
U2 snRNA in transfected cells. A single-strand conformation polymorphism
gel with DNAs extracted from the wild-type and mutated U2 snRNA plasmids
(lanes 1 and 3), their 1:1 mixture (lane 2) and with cDNAs prepared from
HEK293T cells transfected with wild-type (lane 4) and mutated (lane 5) U2
snRNA. (D) Exon inclusion levels of the DQB10602 minigenes mutated in
BPS SNPs and co-transfected with wild-type (indicated with superscript a)
and mutated U2 snRNA plasmids. Exon inclusion in controls transfected
with the same amount of vector DNA (data not shown) was not significantly
different from that in untransfected cells (cf. Fig. 3C). (E) Exon inclusion
levels of minigenes mutated at BP.
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SF1 in gel mobility shift assays. BP-2U-carrying RNAs
(haplotypes A226T224 and G-26T224, Fig. 4A) showed signifi-
cant gel shifts, but less than the yBPS control, consistent with
a higher exon inclusion of the yBPS- than IVS3-24T-contain-
ing minigenes (Figs 2B and 3C). In contrast, SF1 binding to
BP-2C or BP-2A RNAs (haplotypes A226C224, A-26A224,
G226C224, G226A224) was weak or absent even at the
highest SF1 concentration. SF1 mutated in residues that inter-
act with BP-2 or BP-4 (21) had impaired binding to yBPS and
a BP-2U BPS (Fig. 4B). Exon inclusion levels of BPS mutants
correlated with SF1 binding (r ¼ 0.88, P ¼ 0.02, Supplemen-
tary Material, Fig. S2), suggesting that exon 4 splicing was
determined to a large extent by the strength of specific
SF1–BPS interactions in vitro.
Next, we tested if U2 snRNA–BPS base-pairing can alter
exon inclusion. We cotransfected DQB10602 reporters with
plasmids expressing U2 snRNA and carrying complementary
mutations in the BPS-interacting region. Surprisingly, despite
high expression of mutated U2 snRNA (Fig. 4C) and repeated
experiments with several vectors, we observed no significant
decrease of transient D4 (Fig. 4D).
Predominance of hBPS point mutations in BP and BP-2
Comparison of previously published disease-associated single-
base substitutions in hBPS showed that these alterations
occurred only in BP and BP-2 (Table 1). Their biased distri-
bution across BPS ( p ¼ 1026, binomial test for both BP and
BP-2) suggests that point mutations in the remaining BPS posi-
tions give rise to no or only minor splicing defects and do not
produce recognizable phenotypes. Since BP-2U mutations
markedly impair SF1–BPS interactions (Fig. 4A) (20,25) and
BPSs in naturally occurring BP-2U substitutions (Table 1) were
similar to those in DQB1 IVS3 (Fig. 2A), the associated splicing
abnormalities of hBP-2 mutations are likely to arise through
weakened SF1 binding. Because BP mutations efficiently
reduce these interactions as well (20,25), the majority, if not
all, single nucleotide substitutions in hBPS may affect splicing
via impaired SF1–BPS binding.
A predominance of A!G transitions in BP (Table 1)
suggested that hBP mutated to pyrimidines, which can be
used for productive lariat formation (26), generate more
natural transcripts than BP-A!G transitions, consistent with
a more severe reduction of the first and second splicing steps
in vitro observed for guanine-containing substrates (27). To
test this in vivo, we examined DQB1 isoforms after transfec-
tion of the 0602 minigenes mutated at BP into 293T cells.
The transition mutant (BP-A!G) gave the highest expression
of transient D4, whereas both transversions yielded lower
amounts (Fig. 4E). However, because BP transversions and
transitions in very short introns may generate similar levels
of exon skipping (28), their phenotypic outcome is likely to
be influenced by intronic sequences. This is further supported
by comparison of the splicing phenotype of human BPS alt-
erations with intronic length, suggesting that mutations in
very short introns, particularly those in BP-2, tend to result
in intron retention, whereas those in longer introns usually
skip downstream exons (Table 1).
Phenotypic consequences of BPS substitutions are
influenced by the intronic context
To further test these predictions, we examined minigenes with
truncated introns (Fig. 5A). When compared with the wild-
type minigene, the truncated 0602 minigene showed negli-
gible exon 4 skipping and substantial intron 3 retention
(Fig. 5A, lane 2). In contrast, a chimeric construct, in which
exon 4 and flanking intronic sequences were derived from the
D4-lacking allele (050101, Fig. 1C), produced transcripts that
retained only minimal amounts of intron 3 (Fig. 5A, lane 1).
Since the two minigenes diverged in only four SNPs, we
mutated each position in the former construct and examined
the splicing pattern. IVS3-24A!T showed the most promi-
nent reduction of intron 3 inclusion, whereas mutations in the
Table 1. Single-nucleotide substitutions in hBPS that resulted in recognizable phenotypes
Gene Y25 N24 Y23 U22 R21 A0 Yþ1 Splicing abnormality Reference Intron length
(nt)a
L1CAM A T C C A A!Cb G Activation of a cryptic 30 splice site Rosenthal et al. (104) 829
LIPC C C C C A A!G T Activation of cryptic 30 splice sites Brand et al. (105) .105
FBN2 T T G C A A!G T Exon skipping Putnam et al. (106) 410
HEXB T T G C A A!G T Activation of a cryptic 30 splice site Fujimaru et al. (107) 433
XPCc T A C T G A!G T Exon skipping Khan et al. (108) 2057
HEMB C G T T A A!G T Not determined Ketterling et al. (109) 188
TSC2 G C G T G A!G C Activation of cryptic 30 splice site
and intron retention
Mayer et al. (110) 106
LCATc C C C T!C G A C Complete intron retention Kuivenhoven et al. (31) 83
ITGB4c G G C T!A C A C Intron retention and activation of a
cryptic 30 splice site
Chavanas et al. (30) 88
THc G G C T!A G A T Exon skipping and cryptic 30 splice
site activation
Janssen et al. (111) 238
COL5A1 G A C T!G G A T Exon skipping Burrows et al. (32) 5875
DQB1c C G/A C T/A/Cb G A C Variable exon skipping This study 509–516
aIntron length was determined from www.ensembl.org, except for DQB1.
bArrows and slashes indicate naturally occurring mutations and polymorphisms, respectively.
cBP was determined experimentally as described in each reference. Minigene constructs derived from the remaining genes showed impaired splicing
following mutations of the indicated BP adenosine (J. Kralovicova et al., manuscript in preparation).
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remaining SNPs contributed much less to retention (Fig. 5A),
further supporting the importance of BP-2 uracil in intron 3
removal and exon 4 skipping. Diverse splicing and clinical
outcome of BP-2T substitutions is thus determined by intronic
sequences, most likely involving intron–bridging interactions
mediated by SF1, consistent with the central role of this
protein in yeast cross-intron contacts (29) and with the reten-
tion of short (30,31), but not long introns (Fig. 1A and C) (32)
in disease-causing BP-2T substitutions.
Opposite effects of SR proteins and hnRNPs on
DQB1 splicing
To examine the influence of protein factors known to regulate
splicing on both exon 4 inclusion and intron 3 retention, we
individually cotransfected DQB1 reporters with plasmids
expressing SR proteins, a subset of hnRNPs and several mem-
bers of the CUG-BP and ETR-3 like factor (CELF) protein
family. Surprisingly, transcripts retaining intron 3 were
Figure 5. Opposite effects of hnRNPs and SR proteins on DQB1 splicing. (A) Truncated and chimeric DQB10602 constructs. The size of deleted segments
named 1–5 is in nucleotides. Stars denote SNPs (upper panel). Arrow indicates a replacement of exon 4 and flanking intronic sequences with segments specified
in the lower panel. (B) Opposite effects of SR proteins and hnRNPs I, H and F on intron 3 retention. One microgram of plasmid DNA expressing the indicated
factors was co-transfected with 0.5 mg of the DQB10602 reporter lacking segments 1–5. ES, exon skipping; IR, intron retention. (C) The influence of intron
deletions on the ASF/SF2-induced splicing repression. Reporter constructs shown in (A) were co-transfected with plasmids expressing the wild-type ASF/SF2
(the amount is in micrograms). (D) Mutations introduced in the predicted stem structure in segment 2–3. (E) PTB- and ASF/SF2-mediated alterations of exon
skipping and intron retention in the wild-type and truncated 0602 constructs. Equimolar amounts of constructs lacking RRM1, RRM2 and RS-domains were
cotransfected with 0.5 mg of DQB1 reporter constructs shown below each panel; hd, heteroduplexes.
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increased in cells overexpressing SR proteins in both the trun-
cated (Fig. 5B) and the full-length (data not shown) minigenes.
In contrast, transcripts that retained intron 3 were diminished
in cells overexpressing hnRNP I (polypyrimidine binding
protein, PTB), F and H. The splicing pattern induced by alter-
natively spliced PTB isoforms was similar, except for PTB-T,
which lacks exons 3–10 and RNA recognition motifs (RRM)
1 and 2 (33). Among constructs with serial deletions of
100 bp segments in intron 3 (Fig. 5A), deletion of segment
3 generated maximum ASF/SF2-induced intron retention
(Fig. 5C). This segment was predicted to form significant
RNA secondary structure, but multiple substitutions designed
to remove the most prominent stem–loop (Fig. 5D) had no
effect on intron retention or exon skipping both in the wild-
type and shortened 0602 minigenes (data not shown).
Figure 5E shows DQB1 transcripts after cotransfection of
the wild-type and truncated reporters with plasmids expressing
ASF/SF2 and PTB. Truncations in either intron markedly ele-
vated levels of intron 3-retaining transcripts. In contrast, exon
skipping was promoted by removal of intron 3 sequences,
but was eliminated by truncation of the second intron. The
opposite effects of ASF/SF2 and PTB were dose-dependent
and cotransfection of a constant PTB amount with increasing
amounts of ASF/SF2 and vice versa antagonized the effects of
either protein (data not shown). Importantly, ASF/SF2 lacking
RRM1 or RRM2 lost the intron-retaining activity (Fig. 5E).
The absence of RRM2, but not RRM1, promoted exon skip-
ping of reporters truncated in intron 4/5. Interestingly, a lack
of RS domain did not eliminate repression of intron 3 spli-
cing, but enhanced retention of intron 4/5. RNA binding was
thus essential for the PTB-mediated activation and the ASF/
SF2-induced repression of intron 3 splicing, whereas the RS
domain was dispensable for the ASF/SF2-mediated retention
of weakly spliced intron 3, but not strong intron 4/5.
Exon 4 inclusion is controlled by ESE 5D
Most constructs mutated in exon 4 SNPs reproducibly
increased (E4þ74, E4þ98, Eþ106) or reduced (E4þ89,
E4þ42, E4þ80, Eþ94) exon inclusion. Because D4
expression was most influenced by E4þ74 (Fig. 2C), we
examined this SNP in more detail. A functional SELEX tool
(34) that may facilitate identification of ESEs responsive to
a subset of human SR proteins predicted that E4þ74T/C
may create a putative binding site for SRp40 (TTCCTC74G).
In contrast, E4þ89C/T and E4þ94A/G may reduce the
ASF/SF2 interaction and E4þ106G/A may impair SRp40
binding (arrows in Supplementary Material, Fig. S3). In
cotransfection experiments with plasmids expressing the two
SR proteins, both the wild-type and mutated clones showed
an increase of intron 3 retention, but exon inclusion levels
of mutated clones were similar to the wild-type minigenes
(Fig. 6A). Examination of a series of constructs mutated in
the flanking sequence to maximize and minimize SRp40
matrix scores revealed considerable alterations of exon
inclusion, indicative of the presence of strong ESE/ESSs,
but there was no significant correlation between the matrix
scores and exon inclusion (P ¼ 0.2, Fig. 6B).
Interestingly, an ESE derived by the relative enhancer and
silencer classification by unanimous enrichment (RESCUE)
and termed 5D (8) was present in minigenes that showed
high exon inclusion, but was absent in constructs with high
Figure 6. Identification of splicing regulatory sequences in DQB1 exon 4. (A) Co-transfections of DQB1 reporters mutated in positions predicted by functional
SELEX (34) with SRp40 and wild-type ASF/SF2. The amounts of plasmid DNA are in micrograms. (B) Influence of mutations in a putative SELEX binding site
for SRp40 on exon inclusion. Mutations are underlined and their positions in exon 4 are indicated with a subscript. Matrix scores (m.s.) for SRp40 were derived
as described (34). Mutation 75C introduced a putative binding site for SRp55 (m.s. 3.01), while mutations maximizing the SRp40 score introduced putative
binding sites for ASF/SF2 (m.s. 5.2). (C) Influence of mutations in the 5D consensus (8) on exon inclusion (EI) in cells co-transfected with SRp20. The
amount of SRp20 is in micrograms. Pictogram of ESE 5D is reproduced with permission from Science (8).
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D4. Mutations in the conserved 5D positions (nucleotides 66–
71) to nucleotides that were rare or absent in the 5D consensus
significantly increased D4. The highest increase was observed
for mutations of the last position (E4þ71C), which is invar-
iant in this hexamer. In contrast, mutation 69T!G, which
improves the match to 5D, lowered D4 (Fig. 6C). As with
other SR proteins (Fig. 5B), cotransfection of mutated con-
structs with SRp20, which may bind 5D (8,35,36), increased
intron 3 retention (Fig. 6C); however, the SRp20-induced
increase of D4 was observed for each 5D mutation.
DQB1 exon 4 skipping is increased at
subphysiological temperatures
The spliceosomes assembled on different splice sites are not
identical and physiological conditions may therefore differen-
tially affect the splicing pattern of various messages. As tem-
perature has ambivalent effects on splicing efficiency and exon
inclusion (37) and BPS mutations are often associated with
temperature-sensitive phenotypes in lower organisms (38),
we measured D4 using real-time PCR in homozygous cell
lines maintained at various temperatures prior to RNA ext-
raction. Cells kept at 308C had the highest D4 expression rela-
tive to natural transcripts (Fig. 7A). The D4 levels in cells
maintained at 58C were similar to those observed for physio-
logical temperatures, whereas cells kept at 208C had inter-
mediate levels. Cell lines exhibiting the highest D4 at 378C
had the peak D4 levels also at non-physiological temperatures,
indicating that the differential exon skipping is maintained
under stress conditions. Resuscitation of cells kept at lower
temperatures for additional 24 h at 378C prior to RNA extrac-
tion normalized D4 levels (data not shown). Exon skipping was
also significantly increased for transiently expressed haplotype-
specific minigenes in cells maintained at 308C (Fig. 7B). Thus,
subphysiological temperatures (20 and 308C) enhanced both
the endogenous and exogenous D4 expression across the cell
lines.
DISCUSSION
We have shown the first examples of naturally occurring BPS
haplotypes [DQB1 IVS3-26(A/G), -24(A/C/T)] that influence
gene expression, providing the clearest illustration to date
of haplotype control of AS. Because sDQb are present in
culture supernatants of D4-positive, but not D4-negative cell
lines (11), we propose that their haplotype-specific secretion
is largely determined by IVS3 PPT and BPS variants
through differential recognition of BPS by the KH-QUA2
domain of SF1. Our negative U2 snRNA complementation
data (Fig. 4D) appear to suggest that altered U2 snRNA–
BPS base-pairing, which is obligatory in yeast with virtually
invariant BPS, may not necessarily modify splicing of some
human introns. This notion seems to be supported by a
similar observation in human b-globin (24) and by several
examples of ‘U1 snRNA-independent’ pre-mRNA substrates
(39–44). In addition, if U2 snRNA–BPS interactions substan-
tially contributed to altered splicing caused by phenotype-
associated BPS point mutations (Table 1), one would expect
to see a more uniform distribution of these changes across
hBPS. Interestingly, the two positions (BP and BP-2) have
been shown to be the most effective in reducing SF1–BPS
interaction (20,25). However, without a positive control for
the U2 snRNA complementation, we could not rule out ineffi-
cient entry of transient U2 snRNA into U2 snRNPs, although
RNA preparations were not enriched for snRNPs in previous
studies (23,24). Moreover, we could not completely exclude
cryptic BP usage in some constructs, including those with
PPT SNPs, which may alter interaction of the 65 kDa subunit
of U2 auxiliary factor (U2AF65) with the pre-mRNA and
cooperative interaction between SF1 and U2AF65 that facili-
tates BPS recognition (45,46). However, our BP mapping
showed only a single inverse PCR product, a minigene with
deleted BPS completely repressed splicing (Fig. 2B) and con-
structs with mutated BP-22A showed differential exon
inclusion (Fig. 5E), consistent with differential recognition
of these BPS substitutions in vitro (27). Finally, it is also poss-
ible that additional BPS-interacting factors, including SR pro-
teins (47–49), might play a role in AS of DQB1 and in
splicing defects caused by human BPS substitutions (Table 1).
Membrane proteins are commonly regulated by mechan-
isms that release their soluble forms from its membrane
anchorage (50). Transmembrane domains of a large number
of human and mouse proteins are removed by AS more fre-
quently than expected and often in a tissue-specific manner
(51,52), suggesting that these events are biologically signifi-
cant. Membrane domains interact during the assembly of
class II heterodimers (53), influence the organization of endo-
somal compartments (54), facilitate DM colocalization and
regulate peptide exchange (55). Although D4 are productive
Figure 7. Temperature-sensitivity of exon 4 inclusion. (A) Endogenous D4
expression in lymphoblastoid cell lines homozygous at DQB1. Cells were
grown at the indicated temperatures for 16 h prior to RNA extraction. Exon
skipping was measured using real-time RT–PCR (Supplementary Material,
Fig. S1). Bars indicate SDs from two experiments. (B) Transient D4
expression of allele-specific minigenes in HEK293 cells maintained at the
indicated temperatures for 16 h prior to cell lysis. RT–PCR was with
vector-specific primers.
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transcripts (11) that may modulate immune responses (13,14)
and bind similar peptides as membrane-bound molecules (56),
physiological significance of sDQ and their putative role in
susceptibility to autoimmune disease have been obscure. Inter-
estingly, the highest concentration of sHLA class II molecules
has been observed in individuals carrying DR3 and DR4
alleles (15), which are in linkage disequilibrium with the
D4-producing DQB10302 and 0401 (Figs 1A and 2A). In
addition, higher levels of sHLA class I molecules were
found for HLA-A24 (12), which is linked to DQB10302
and 0401. Future studies should therefore confirm whether
the high D4 production is indeed reflected in increased
levels of sDQb in body fluids.
Excessive amounts of D4 observed for some alleles (Fig. 7)
provoke the hypothesis that the observed temperature-induced
mRNA alterations could influence surface expression of DQ
heterodimers, interactions of the peptide–MHC complexes
with T-cell receptor (TCR) and, ultimately, the course of (or
susceptibility to) autoimmune diseases. Most notably, joint
pain in patients with rheumatoid arthritis (RA), which is
associated with D4-producing DQB1030x and 040x alleles,
has long been linked to low temperatures (57). It can also be
speculated that a well-known latitude gradient in the popu-
lation prevalence of autoimmune disorders, sometimes attrib-
uted to pathogen distribution, ultraviolet radiation or other
environmental or genetic effects, may be influenced by the
temperature gradient. Since temperature-dependency of RA
and other autoimmune disorders, such as systemic lupus,
Behcet disease and ankylosing spondylitis (58), may also
result from altered temperature-induced association and dis-
sociation rates of peptide–MHC interactions with TCR (59),
it will be interesting to examine these possibilities in future
studies.
Although subphysiological temperatures enhanced exon 4
skipping of each allele (Fig. 7), they may also elicit exon
inclusion (60) or inhibit utilization of the cryptic splice site
of other substrates (37). In addition, heat shock has been
shown to activate an alternative 50 splice site (61) and
mutation of the last exon nucleotide produced an aberrant tran-
script not detectable at 318C, which gradually increased up to
398C (62). Our results thus further underline the importance of
fast processing of clinical samples intended for RNA analysis
and temperature control during their transport and storage to
minimize the number of incorrectly spliced transcripts and to
avoid false positive reports of gene deletions, AS or haplotype-
specific mRNA expression.
Alterations of exon inclusion induced by the majority of
exonic SNPs and mutations in putative binding sites for spli-
cing regulatory factors support a high abundance of sequences
that influence pre-mRNA splicing. Interestingly, the range of
exon inclusion levels produced by mutations in natural vari-
ants was smaller than for those introduced in putative splicing
regulatory regions identified by RESCUE-ESE or SELEX
approaches (Figs 2C and 6B). Alterations of exon inclusion
following mutations in exonic SNPs were also less variable
than in previous studies employing random mutations in
coding regions (63,64). For example, 13 of 26 CFTR exon 9
mutations lowered exon inclusion under 15% (range 8–
98%) (64), whereas none of our constructs mutated in
exonic SNPs reduced natural transcripts below this level
(range 18–76%, Fig. 2C). This suggests that mutations in
the coding region that reduce exon inclusion below an exon-
or gene-specific threshold are subject to significant selection
at the level of pre-mRNA splicing.
Three of eight tested exonic SNPs (þ42, þ98 and þ106)
were located in putative RESCUE-ESE-derived hexamers (8).
Mutations in two of them (þ106G and þ98C), which were
close to the 50 splice site and encoded non-conservative
amino acid substitutions, were predicted to remove enhancers,
but they significantly reduced D4 (Fig. 2C). E4þ42A, which
was expected to retain ESE 5A/3G (8), had the opposite
effect, indicating that the predictive value of putative ESEs
to activate splicing is very limited without considering other
interactions. In contrast, mutations in ESE 5D located in the
middle part of the exon generated predicted exon inclusion
levels, including the 68C!A transversion (Fig. 6C), which
corresponds to the mutation that had caused exon-skipping
in a heterologous context (8). In addition, 5D is likely to con-
tribute to exon definition across species since the AUCUUC
consensus is invariant in the mouse (GenBank accession
nos K00008, K00111, M60562 and K00116), rat (M15356),
pig (AY459305), cow (AY212029), sheep (Z27401), goat
(AY464653), cat (AY152833), dog (Y07947) and possum
(AY271265).
SR proteins typically promote exon inclusion through
binding to exonic ESEs, but they may also repress splicing
in vitro and in vivo (Fig. 5; 65–70). Similarly, PTB has
been regarded as a general repressor of splicing (71), but over-
expressed PTB can also promote exon inclusion (Fig. 5)
(72,73). The observed opposite effects of hnRNPs and SR pro-
teins on splicing of intron 3 and at least some of the previous,
seemingly contradictory, results can be reconciled by antagon-
istic effects of these factors on splice site selection. Although
exceptions have been noted (74), ASF/SF2 and other SR pro-
teins generally activate proximal splicing, whereas distal spli-
cing is promoted by hnRNP A1 (65,66,75–78). DQB1 intron 3
is very weak, with the 50 splice sites of exon 3 and exon 4
effectively competing for splicing to exon 6. Therefore, the
SR-induced intron 3 retention can be explained by a repression
of the distal 50 splice site (i.e. 50 splice site of exon 3) and/or
promotion of the proximal 50 splice site (i.e. 50 splice site
of exon 4). Similarly, hnRNP-mediated decrease of intron
3-containing transcripts would result from a repression of
the proximal splice site and/or promotion of distal splicing.
Some factors did not alter isoform ratios (Fig. 5B), but we
could not exclude poor transient expression over high endo-
genous levels, as we did not have antibodies against hnRNP
A1, hSlu7 and CELF proteins. However, the negative result
with hnRNP A1 (Fig. 5B) resembles a previous observation
(79) and may reflect substrate-specific requirements. Despite
this drawback, examination of a sizeable panel of hnRNPs
and SR proteins, which colocalize in discrete regions of the
nucleus (80,81), highlights the opposite effects of the two
protein families on the selection of competing splice sites. It
also suggests that the network of antagonistic interactions
that balance splice site selection may be more extensive and
that future studies may substantially add to currently known
examples (65,66,75–78,82–85). In addition, the novel multi-
allelic splicing reporter system described here will be useful
to study interactions across the highly polymorphic splice
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acceptor site and to test whether the requirement for U2
snRNA base-pairing with BPS is alleviated by SR proteins,
as proposed earlier for U1 snRNP interactions with the
50 splice site (40,41).
A prominent decrease of D4 observed for IVS3-6C!T
mutations (Fig. 2B and D) can be explained by improved inter-
actions of PPT with RRM1 of U2AF65 or competition with
other RNA binding proteins that preferentially recognize
polyuridine-rich sequences (86,87). The pentauridine stretch
characteristic of the 05 lineage (Fig. 2A) was sufficient to
maintain high exon inclusion in the cell line TEM despite wea-
kened BPS of the DQB1050301 allele (Figs 1A and 2A).
Although uridines are generally the preferred pyrimidine in
PPT (88,89), IVS-6U!C substitutions may (Fig. 2B) or may
not (90) affect exon inclusion. Differential outcome of T/C
substitutions in identical PPT positions relative to the 30 AG
could be due to intron-specific binding registers of U2AF65
(87) and/or the presence (90) or absence (Fig. 2A) of
purines in the vicinity of the 30 splice site that weaken PPT
recognition. Because RRM1 of U2AF65 does not crosslink to
a unique set of residues at the 30 end of PPT (87), prediction
of splicing phenotypes caused by point mutations in this
region may be more problematic than those in hBPS.
MATERIALS AND METHODS
Multi-allelic splicing reporter system
A 2.2 kb region containing exons 3–6 was amplified using
primers A and F (Fig. 1B) with the Expand Long Template
PCR System (Roche, USA) and DNA from cell lines homozy-
gous at DQB1 (Figs 1A and 2A). Primers are shown in
Supplementary Material, Table S2. Homozygosity and allele-
specificity of template DNA was confirmed with a panel of
HLA microsatellites and sequence-based typing of DQB1
and DRB1 as described (91). Gel-purified DNA was cloned
into pCR3.1 (Invitrogen, USA). Mutated minigene constructs
were prepared by overlap-extension PCR and validated by
sequencing as described (92).
Sequence variability of DQB1 introns
Introns 3–5 of 10 DQB1 alleles were sequenced directly using
amplicons obtained from homozygous DNA with PCR
primers A-S1, A-F or G-F. Sequencing primers S1–S7 are
schematically shown in Figure 1B. The nucleotide diversity
or the average number of nucleotide differences per site
(P(i )) (93) was computed using DNA SP software (version
4) (94) with pairwise removal of the alignment gaps
(Fig. 1D). The window and step sizes were 30 and 2 nucleo-
tides, respectively.
Expression plasmids and antibodies
Plasmids expressing ROD1 (95), PTB1, PTB2 (96), PTB4 (97),
PTB-T (33), ETR-3, CUG-BP, CELF4 (83,98), 9G8, SC35,
ASF/SF2, SRp30c, SRp40, SRp55, SRp75 (81), U2 snRNA
(24), hSLu7 (99), hnRNP A1, H and K were obtained as a gen-
erous gift from G. Ast, D. Black, J. Caceres, T. Cooper,
A. Krainer, A. Mayeda, H. Okayama, R. Reed, Z. Ronai,
W. Rigby, G. Screaton, C. Smith and A. Weiner. hnRNPs C1,
F and G were cloned from a cDNA library using primers
shown in Supplementary Material, Table S2. pET-15b-hnRNP
H obtained from D. Black was subloned into Xho I and
BamHI sites of pCR3.1. Mutated ASF/SF2 constructs were
obtained from J. Caceres. In addition to previously described
construct (24), U2 snRNA was cloned into pCR3.1 and
pGEM using primers U2-F/R. All clones were validated by
nucleotide sequencing before transfection. The expression of
a subset of proteins was confirmed by Western blotting with
whole-cell lysates using antibodies against hnRNP I, H, F
and K generously provided by D. Black, G. Dreyfus,
T. Tamura and C. Smith.
Homozygous cell lines
Cell lines or DNA samples carrying the indicated alleles
(Figs 1A and 2A) were purchased from the European Cell
Culture Collection (Salisbury, UK) or were a gift from
S. Marsh and N. Mayor, Anthony Nolan Research Institute.
Cell lines were grown in RPMI1640 with 1% glutamine (v/v)
supplemented with 10% fetal calf serum. DNA was extracted
as described (92). Total RNA was isolated using RNeasy
Mini Kit (Qiagen, Germany). First-strand cDNA was reverse
transcribed using oligo(dT)15 primers and Moloney murine
virus reverse transcriptase (M-MLV H2; Promega, USA)
according to manufacturer’s recommendations.
Transfections
HeLa and 293T cells were grown under standard conditions in
RPMI1640 supplemented with 10% (v/v) fetal calf serum
(Gibco BRL, USA). Transient transfections were performed
in 6- or 12-well plates using FuGENE 6 (Roche) according
to manufacturer’s recommendations. Cells were harvested
with trypsin 48 h post-transfection.
Detection of DQB1 isoforms
Total RNA was isolated using RNeasy Mini Kit (Qiagen) or
Tri-reagent (Sigma, USA) and treated with DNaseI (Ambion,
USA). First-strand cDNA was reverse transcribed using
oligo(dT)15 primers and Moloney murine virus reverse tran-
scriptase (M-MLV H2; Promega) according to manufacturer’s
recommendations. Exon inclusion levels were measured on
ethidium bromide-stained gels with FluorImager 595 using
FluorQuant and Phoretix software (Nonlinear Dynamics Inc.,
USA). DNA bands were extracted from the gel and sequenced
to confirm the identity of each fragment. The number of PCR
cycles was 28 or lower to maintain approximately linear
relationship between the RNA input and signal. Design of
real-time RT–PCR with primers/probes T26–T45 is shown
in Supplementary Material, Figure S1. Standard curves were
constructed using serial dilutions of DNA extracted from plas-
mids containing allele-specific inserts cloned using amplicons
that were derived from lymphoblastoid cell lines homozygous
at DQB1 (Figs 1A and 2A).
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Detection of BPS haplotypes and U2 snRNA expression
A 153 nucleotide fragment containing the BPS-interacting
region of U2 snRNA was amplified using single-strand con-
firmation primers (SSCP)-F/R (Supplementary Material,
Table S2). SSCP assays were carried out as described (92).
ARMS–PCR (19) for the population screening of BPS associ-
ated with the lowest exon inclusion (Fig. 3C and D) was with
DNA samples ascertained as described previously (100).
Ethics approval was granted by a local committee. The speci-
ficity of ARMS–PCR was tested using DNAs isolated from
plasmids mutated in BPS (Fig. 3C).
RNA secondary structure predictions
The lowest free energy structures were predicted using
enhanced free energy minimization algorithms and plotted
(Fig. 5D) with the RNA Structure (version 3.7) (101).
Gel mobility shift assays
Gel shift experiments were carried out as described (21). Ten
microlitre reactions contained 32 mM Tris–HCl (pH 8.0),
160 mM NaCl, 8 mM imidazole, 4 mM b-mercaptoethanol,
2.5 mg tRNA, 0.01 pmol of 50 [32P]-ATP-labelled oligoribo-
nucleotides (Biospring, Germany).
Branchpoint mapping
A two-exon fragment amplified with primers A and D
(Fig. 1B) using homozygous DNA was cloned into pGEM-T
Easy (Promega, USA), linearized with Sal I and in vitro trans-
cribed using MAXIscript and m7G(50)ppp(50)G cap analog
(Ambion) in the presence and absence of [a-32P]-UTP. Pre-
mRNA was incubated with 30% of HeLa nuclear extracts
(4C, Belgium), ATP (0.5 mM), creatine phosphate (20 mM),
MgCl2 (2 mM), 20 U of RNasin (Promega), PVA (2.6%) and
30% of buffer E (5% glycerol, 0.5 mM dithiothreitol, 0.2 mM
EDTA, 100 mM KCl and 20 mM HEPES, pH 7.8) in a 25 ml
volume at 308C for 3 h. Reactions were stopped by adding
proteinase K at a final concentration of 200 ng/ml. RNA was
extracted with phenol, and precipitated with ethanol. Isotopi-
cally labeled RNA was loaded onto 5% PAGE (Fig. 3A).
Non-labeled RNA was reverse-transcribed with M-MLV
(H2) RT (Promega, USA) and primer BP-RT. Two microlitres
of the first-strand cDNA were used as a template for PCR
with primers BP-F/BP-R at an annealing temperature of
568C. Amplification primers were designed using the Oligo
programme (version 6.63) according to an expected cDNA
template. A single PCR product of 113 nucleotides was gel-
purified and sequenced as described (92).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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